Certainly, the balance between extracellular and intracellular ADO concentrations, as well as the activity of CD39 and CD73, is an essential factor to determine what role the adenosinergic pathway will play in cancer, whether a hero or a villain. This evidence concerns the gene ENTPD1 and cancer.